bms 387032
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00292864)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 7INHIBITOR
CDK7 inhibitor
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1- Mol. weight
- 380.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL296468 ↗
Also known as
- bms387032
- bms 387032
- bms-387032
- bms-387032
- bms-387032
- n-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide
- sns 032
- sns-032
- sns-032
- sns-032
- sns-032
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00446342 | Phase 1 | Feb 1, 2007 | Sunesis Pharmaceuticals |
| NCT00292864 | Phase 1 | Jan 1, 2006 | Sunesis Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunesis Pharmaceuticals | For profit | 2 | 2 | 1 | 2006 |
1 organizations
Page 1 / 1